Pregabalin: a review of its use in adults with generalized anxiety disorder (Q34434641)

2 August 2017

title

Pregabalin: a review of its use in adults with generalized anxiety disorder (English)

1 reference

2 August 2017

James E Frampton

1

1 reference

2 August 2017

publication date

1 September 2014

1 reference

2 August 2017

1 reference

2 August 2017

volume

28

1 reference

2 August 2017

issue

9

1 reference

2 August 2017

page(s)

835-854

1 reference

Current considerations in the treatment of generalized anxiety disorder

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0192-0

Pharmacotherapy of generalized anxiety disorder: focus and update on pregabalin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0192-0

Human and economic burden of generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0192-0

Generalized Anxiety Disorder and major depressive disorder comorbidity in the National Survey of Mental Health and Well-Being.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0192-0

Risk factors for suicide completion in major depression: a case-control study of impulsive and aggressive behaviors in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0192-0

Generalized anxiety disorder: diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0192-0

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0192-0

Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0192-0

Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0192-0

Pregabalin pharmacology and its relevance to clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0192-0

Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0192-0

Elucidating the mechanism of action of pregabalin: α(2)δ as a therapeutic target in anxiety

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0192-0

A Comparison of the Pharmacokinetics and Pharmacodynamics of Pregabalin and Gabapentin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0192-0

Clinical pharmacokinetics of pregabalin in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0192-0

Identification of the alpha2-delta-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0192-0

Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0192-0

Structure-activity relationships of pregabalin and analogues that target the alpha(2)-delta protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0192-0

Anxiolytic-like activity of pregabalin in the Vogel conflict test in α2δ-1 (R217A) and α2δ-2 (R279A) mouse mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0192-0

Pharmacokinetics of pregabalin in subjects with various degrees of renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0192-0

Pregabalin in generalized anxiety disorder: a placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0192-0

Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0192-0

Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0192-0

Pregabalin long-term treatment and assessment of discontinuation in patients with generalized anxiety disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0192-0

Long-term efficacy of pregabalin in generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0192-0

Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0192-0

Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0192-0

Impact of gastrointestinal symptoms on response to pregabalin in generalized anxiety disorder: results of a six-study combined analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0192-0

The efficacy of pregabalin and benzodiazepines in generalized anxiety disorder presenting with high levels of insomnia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0192-0

Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: a pooled analysis of 6 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0192-0

Pregabalin: dose-response relationship in generalized anxiety disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0192-0

Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0192-0

Dose-response relationship of pregabalin in patients with generalized anxiety disorder. A pooled analysis of four placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0192-0

Pregabalin for the treatment of generalised anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0192-0

Long-term treatment of anxiety disorders with pregabalin: a 1 year open-label study of safety and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0192-0

The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0192-0

A double-blind, placebo- and positive-internal-controlled (alprazolam) investigation of the cognitive and psychomotor profile of pregabalin in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0192-0

Characterizing and understanding body weight patterns in patients treated with pregabalin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0192-0

A signal for an abuse liability for pregabalin--results from the Swedish spontaneous adverse drug reaction reporting system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0192-0

Pregabalin and its potential for abuse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0192-0

A cost-utility analysis of pregabalin versus venlafaxine XR in the treatment of generalized anxiety disorder in Portugal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0192-0

Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0192-0

Modelling the cost-effectiveness of pregabalin versus usual care in daily practice in the treatment of refractory generalised anxiety disorder in Spain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0192-0

The cost effectiveness of pharmacological treatments for generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0192-0

Broadening of Generalized Anxiety Disorders Definition Does not Affect the Response to Psychiatric Care: Findings from the Observational ADAN Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0192-0

Pregabalin for the treatment of generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0192-0

Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0192-0

How well do randomized controlled trial data generalize to 'real-world' clinical practice settings? A comparison of two generalized anxiety disorder studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0192-0

Effects of pregabalin on sleep in generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0192-0

Clinical practice. Generalized anxiety disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0192-0

Efficacy and safety of treatments for refractory generalized anxiety disorder: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0192-0

Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0192-0

An effect-size analysis of pharmacologic treatments for generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0192-0

One-year prevalence of subthreshold and threshold DSM-IV generalized anxiety disorder in a nationally representative sample

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0192-0

Potential for pregabalin abuse or diversion after past drug-seeking behavior

21 January 2018

1 reference

12 December 2020

Adjunctive therapy with pregabalin in generalized anxiety disorder patients with partial response to SSRI or SNRI treatment

1 reference

12 December 2020

Pregabalin versus SSRIs and SNRIs in benzodiazepine-refractory outpatients with generalized anxiety disorder: a post hoc cost-effectiveness analysis in usual medical practice in Spain

1 reference

12 December 2020

The association between anxiety disorders and suicidal behaviors: a systematic review and meta-analysis

1 reference

12 December 2020

Pregabalin for the treatment of generalized anxiety disorder: an update

1 reference

12 December 2020

Switching from long-term benzodiazepine therapy to pregabalin in patients with generalized anxiety disorder: a double-blind, placebo-controlled trial

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder

1 reference

12 December 2020

A meta-analysis of the efficacy of pregabalin in the treatment of generalized anxiety disorder

1 reference

12 December 2020

A comparative cost-analysis of initiating pregabalin or SSRI/SNRI therapy in benzodiazepine-resistant patients with generalized anxiety disorder in Spain

1 reference

12 December 2020

Understanding comorbidity with depression and anxiety disorders.

1 reference

12 December 2020

The adverse event profile of pregabalin across different disorders: a meta-analysis

1 reference

12 December 2020

Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine

1 reference

12 December 2020

10.1007/S40263-014-0192-0

Identifiers

DOI

1 reference

2 August 2017

1 reference